海藻酸钙对骨质疏松症大鼠骨骼肌SDF-1含量和骨密度的影响

摘要 目的：探讨海藻酸钙对骨质疏松症大鼠骨骼肌基质细胞衍生因子-1（Stromal Cell-derived Factor-1，SDF-1）含量和骨密度的影响。方法：骨质疏松症大鼠（n=48）随机平分为三组-模型组、尼尔雌醇组与海藻酸钙组，在建模后1周后三组分别给予双蒸水、0.1 mg/100 g尼尔雌醇与37.5 mg/mL海藻酸钙/枸杞多糖凝胶微球水溶液灌胃治疗，1 次/d，检测大鼠骨骼肌SDF-1含量和骨密度变化情况。结果：（1）尼尔雌醇组与海藻酸钙组给药第4周与第8周的血清钙离子含量高于模型组（P<0.05），磷离子含量低于模型组（P<0.05），尼尔雌醇组与海藻酸钙组对比差异有统计学意义（P<0.05）；（2）尼尔雌醇组与海藻酸钙组给药第4周与第8周的骨骼肌SDF-1含量低于模型组（P<0.05），海藻酸钙组低于尼尔雌醇组（P<0.05）；（3）尼尔雌醇组与海藻酸钙组给药第4周与第8周的腰椎和股骨骨密度高于模型组（P<0.05），海藻酸钙组低于尼尔雌醇组（P<0.05）；（4）尼尔雌醇组与海藻酸钙组给药第4周与第8周的股骨最大载荷、最大应力高于模型组(P<0.05)，海藻酸钙组高于尼尔雌醇组（P<0.05）；（5）海藻酸钙组造血细胞数量较多，骨皮质结构较完整，致密均匀粗壮，小梁数目明显增多，骨髓腔变小。结论：海藻酸钙在骨质疏松症大鼠的应用能抑制骨骼肌SDF-1的释放，有助于提高骨密度，改善骨生物力学指标，提高血清钙离子含量，降低磷离子含量。

Effects of Calcium Alginate on SDF-1 Content and Bone Density of Skeletal Muscle in Rats with Osteoporosis

ABSTRACT Objective: To investigate the effects of calcium alginate on the content of skeletal muscle stromal cell-derived factor-1 (SDF-1) and bone density in rats with osteoporosis. Methods: Osteoporosis rats (n=48) were randomly divided into three groups-model group, nylestriol group and calcium alginate group. After modeling, the three groups were given double distilled water, 0.1 mg/ 100 g nilestriol, 37.5 mg/mL calcium alginate/Lycium barbarum polysaccharide gel microsphere aqueous solution were treated by intragastric administration, once a day, and the changes of SDF-1 content and bone density in rat skeletal muscle were detected. Results: (1) The serum calcium ion content of the nilestriol group and the calcium alginate group were higher than that of the model group at the 4th and 8th week of administration(P<0.05), and the phosphorus ion content were lower than that of the model group (P<0.05). There were statistically significant difference compared between the nylestriol group and the calcium alginate group (P<0.05). (2) The levels of SDF-1 in skeletal muscle of the nilestriol group and the calcium alginate group were lower than those of the model group at the 4th and 8th week of administration (P<0.05), and the calcium alginate group were lower than that of the nilestriol group (P<0.05). (3) The bone mineral density of the lumbar spine and femur in the nilestriol group and the calcium alginate group were higher than that of the model group at the 4th and 8th week of administration(P<0.05), and the calcium alginate group were lower than that of the nilestriol group (P<0.05). (4) The maximum load and maximum stress of the femur in the nilestriol group and the calcium alginate group were higher than that of the model group at the 4th and 8th week of administration(P<0.05), and the calcium alginate group were higher than that of the nilestriol group (P<0.05). (5) The number of hematopoietic cells in the calcium alginate group were larger, the cortical bone structure were relatively complete, dense and uniform, the number of trabeculae increased significantly, and the bone marrow cavity became smaller. Conclusion: The application of calcium alginate in osteoporotic rats can inhibit the release of SDF-1 in skeletal muscle, increase bone density, improve bone biomechanical indexes, increase serum calcium ion content, and reduce phosphorus ion content.